Author: Li, Xiaoquan; Lidsky, Peter; Xiao, Yinghong; Wu, Chien-Ting; Garcia-Knight, Miguel; Yang, Junjiao; Nakayama, Tsuguhisa; Nayak, Jayakar V.; Jackson, Peter K.; Andino, Raul; Shu, Xiaokun
Title: Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models Cord-id: ek8j5rpx Document date: 2020_10_28
ID: ek8j5rpx
Snippet: More than a million people have now died from COVID-19, because of infection with the SARS-CoV-2 coronavirus. Currently, the FDA has approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though very recent data from WHO showed little if any COVID19 protective effect. Here we report that ethacridine, a safe and potent antiseptic use in humans, effectively inhibits SARS-CoV-2, at very low concentrations (EC(50) ~ 0.08 μM). Ethacridine was identified through a high-throug
Document: More than a million people have now died from COVID-19, because of infection with the SARS-CoV-2 coronavirus. Currently, the FDA has approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though very recent data from WHO showed little if any COVID19 protective effect. Here we report that ethacridine, a safe and potent antiseptic use in humans, effectively inhibits SARS-CoV-2, at very low concentrations (EC(50) ~ 0.08 μM). Ethacridine was identified through a high-throughput screening of an FDA-approved drug library in living cells using a fluorescent assay. Interestingly, the main mode of action of ethacridine is to inactivate virus particles, preventing binding to the host cells. Thus, our work has identified a potent drug with a distinct mode of action against SARS-CoV-2.
Search related documents:
Co phrase search for related documents- activity reporter and low concentration: 1
- additional step and log reduction: 1
- log reduction and low concentration: 1, 2
- log reduction and low middle: 1, 2
Co phrase search for related documents, hyperlinks ordered by date